Aiming to improve the clinical outcomes of people with Parkinson’s disease, pharmaceutical company UCB is partnering with key U.K. and U.S. nonprofits to establish the Patient Engagement Council for Parkinson’s Research. UCB is teaming up
Parkinsons Articles
Age at Disease Onset Results in Distinct Speech Patterns
People with early- or late-onset Parkinson’s disease tend to have different characteristic changes in their speech, according to a new study. The study, “Distinct patterns of speech disorder in early-onset and late-onset de-novo Parkinson’s disease,” was
Cala Health Raises $77M for Bioelectronic Devices for Tremors
Cala Health has raised $77 million that will support further innovations of the company’s expertise — bioelectronic medicine — to explore conditions beyond essential tremor, including Parkinson’s disease and other neurological conditions. The funding also will
‘Yours, Truly’ Campaign Focuses on Non-motor Symptoms
To heighten awareness and understanding of non-motor Parkinson’s disease symptoms such as hallucinations and delusions, Acadia Pharmaceuticals and StoryCorps have teamed up to open Yours, Truly, a multicultural storytelling campaign. The national effort, which also seeks
Swedish Researchers Develop Tools to Manage Care More Effectively
A Swedish group of doctors and researchers are working to develop new tools and models to more effectively manage and treat patients with Parkinson’s disease. The group, led by Per Odin, MD, PhD, professor at
1st Trial of Anesthetic Ketamine for Depression in Parkinson’s Wins $2M
Two scientists at Yale University were awarded $2 million from the Michael J. Fox Foundation to conduct the first clinical trial investigating the use of ketamine — a powerful anesthetic — as a treatment for
Meditation Helps Me Seek the Quiet Mind
The “pause between” is my new Parkinson’s self-management tool. I use it every day to help me switch from old ways of reacting to the “flicker effect” (dysregulated systems). It provides improved threshold management and
STAR Molecule to Restore GCase Activity Showing Early Potential
An oral candidate therapy for Parkinson’s disease called GT-02287 lowered the levels of alpha-synuclein accumulation and inflammation, and lessened behavioral deficits in animal models of the disease. “We are working diligently to advance this breakthrough compound to
Phase 2 Trial Planned for KM-819 as Disease-modifying Therapy
Fascinate Therapeutics plans to launch a Phase 2 clinical trial into the safety and early efficacy of KM-819 as a potential therapy for Parkinson’s disease. This follows the approval by the U.S. Food and Drug Administration of
50 Columns Later, I’m Still Inspired by My Parkinson’s Community
According to a 2013 article in The New York Times, the average American knows about 600 people. Since the debut of “Life, Lemons, and Lemonade” over two years ago, I have met many doctors, community
New Guidelines for Dopaminergic Therapy Set for Early Parkinson’s
The American Academy of Neurology (AAN) has issued a new group of guidelines designed to aid clinicians in prescribing the most effective and appropriate dopaminergic medications — those that increase or mimic dopamine — to
Mitochondrial Dysfunction Enough to Cause Parkinson’s in Mice
Mitochondrial dysfunction in dopamine-producing brain cells is sufficient to cause Parkinson’s disease, according to a new study done in mice. The study, “Disruption of mitochondrial complex I induces progressive parkinsonism,” was published in Nature. Parkinson’s is